Cedilla Therapeutics, Inc.

John Feutrill

Louise Clare Kirman

Justin Ripper

Carl Eric Schwartz

Wojtek Michowski

Dale A Porter, Jr

Thomas P Blaisdell

John Paul Sherrill

The present disclosure provides compounds according to Formula I or a pharmaceutically acceptable salt thereof: wherein each variable is as defined and described herein, compositions thereof, and methods of using the same for the inhibition of CDK, and the treatment of CDKrelated diseases and disorders.

CDK2 inhibitors and methods of using the same

The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

Growing community of inventors

Rosanna, Australia

John Feutrill